Show simple item record

dc.contributor.authorGalvan, GC
dc.contributor.authorFriedrich, NA
dc.contributor.authorDas, S
dc.contributor.authorDaniels, JP
dc.contributor.authorPollan, S
dc.contributor.authorDambal, S
dc.contributor.authorSuzuki, R
dc.contributor.authorSanders, SE
dc.contributor.authorYou, S
dc.contributor.authorTanaka, H
dc.contributor.authorLee, Y-J
dc.contributor.authorYuan, W
dc.contributor.authorde Bono, JS
dc.contributor.authorVasilevskaya, I
dc.contributor.authorKnudsen, KE
dc.contributor.authorFreeman, MR
dc.contributor.authorFreedland, SJ
dc.coverage.spatialSwitzerland
dc.date.accessioned2024-07-03T14:15:21Z
dc.date.available2024-07-03T14:15:21Z
dc.date.issued2023-12-21
dc.identifierARTN 1251297
dc.identifier.citationFrontiers in Oncology, 2023, 13 pp. 1251297 -en_US
dc.identifier.issn2234-943X
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/6287
dc.identifier.eissn2234-943X
dc.identifier.eissn2234-943X
dc.identifier.doi10.3389/fonc.2023.1251297
dc.identifier.doi10.3389/fonc.2023.1251297
dc.description.abstractINTRODUCTION: We previously reported that cholesterol homeostasis in prostate cancer (PC) is regulated by 27-hydroxycholesterol (27HC) and that CYP27A1, the enzyme that converts cholesterol to 27HC, is frequently lost in PCs. We observed that restoring the CYP27A1/27HC axis inhibited PC growth. In this study, we investigated the mechanism of 27HC-mediated anti-PC effects. METHODS: We employed in vitro models and human transcriptomics data to investigate 27HC mechanism of action in PC. LNCaP (AR+) and DU145 (AR-) cells were treated with 27HC or vehicle. Transcriptome profiling was performed using the Affymetrix GeneChip™ microarray system. Differential expression was determined, and gene set enrichment analysis was done using the GSEA software with hallmark gene sets from MSigDB. Key changes were validated at mRNA and protein levels. Human PC transcriptomes from six datasets were analyzed to determine the correlation between CYP27A1 and DNA repair gene expression signatures. DNA damage was assessed via comet assays. RESULTS: Transcriptome analysis revealed 27HC treatment downregulated Hallmark pathways related to DNA damage repair, decreased expression of FEN1 and RAD51, and induced "BRCAness" by downregulating genes involved in homologous recombination regulation in LNCaP cells. Consistently, we found a correlation between higher CYP27A1 expression (i.e., higher intracellular 27HC) and decreased expression of DNA repair gene signatures in castration-sensitive PC (CSPC) in human PC datasets. However, such correlation was less clear in metastatic castration-resistant PC (mCRPC). 27HC increased expression of DNA damage repair markers in PC cells, notably in AR+ cells, but no consistent effects in AR- cells and decreased expression in non-neoplastic prostate epithelial cells. While testing the clinical implications of this, we noted that 27HC treatment increased DNA damage in LNCaP cells via comet assays. Effects were reversible by adding back cholesterol, but not androgens. Finally, in combination with olaparib, a PARP inhibitor, we showed additive DNA damage effects. DISCUSSION: These results suggest 27HC induces "BRCAness", a functional state thought to increase sensitivity to PARP inhibitors, and leads to increased DNA damage, especially in CSPC. Given the emerging appreciation that defective DNA damage repair can drive PC growth, future studies are needed to test whether 27HC creates a synthetic lethality to PARP inhibitors and DNA damaging agents in CSPC.
dc.formatElectronic-eCollection
dc.format.extent1251297 -
dc.languageeng
dc.language.isoengen_US
dc.publisherFRONTIERS MEDIA SAen_US
dc.relation.ispartofFrontiers in Oncology
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subject27-hydroxycholesterol (27HC)
dc.subjectCYP27A1
dc.subjectDU145 (prostate) cancer cell line
dc.subjectLNCaP (prostate cancer cell)
dc.subjecthydroxycholesterol
dc.subjectprostate cancer
dc.title27-hydroxycholesterol and DNA damage repair: implication in prostate cancer.en_US
dc.typeJournal Article
dcterms.dateAccepted2023-12-04
dc.date.updated2024-07-03T14:14:39Z
rioxxterms.versionVoRen_US
rioxxterms.versionofrecord10.3389/fonc.2023.1251297en_US
rioxxterms.licenseref.startdate2023-12-21
rioxxterms.typeJournal Article/Reviewen_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/38188290
pubs.organisational-groupICR
pubs.organisational-groupICR/Primary Group
pubs.organisational-groupICR/Primary Group/ICR Divisions
pubs.organisational-groupICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-groupICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.publication-statusPublished online
pubs.publisher-urlhttp://dx.doi.org/10.3389/fonc.2023.1251297
pubs.volume13
icr.researchteamPrCa Targeted Therapyen_US
dc.contributor.icrauthorDe Bono, Johann
icr.provenanceDeposited by Mr Arek Surman on 2024-07-03. Deposit type is initial. No. of files: 1. Files: 27-hydroxycholesterol and DNA damage repair implication in prostate cancer.pdf


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/